Tech Company Financing Transactions
Neuraly Funding Round
On 7/19/2018, Neuraly announced $36 million in Series A funding from D&D Pharmatech, Dongkoo Bio&Pharma and Geon Investment.
Transaction Overview
Company Name
Announced On
7/19/2018
Transaction Type
Venture Equity
Amount
$36,000,000
Round
Series A
Investors
Proceeds Purpose
The company will use the proceeds to advance its pipeline surrounding NLY01.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Germantown, MD 20874
USA
Germantown, MD 20874
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
Neuraly, a startup biotech company, was formed in 2016 following foundational research by world class neuroscientists led by Ted Dawson, M.D., Ph.D., Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases and Director of the Institute for Cell Engineering at the Johns Hopkins School of Medicine.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Seulki Lee
Browse more venture capital transactions:
Prev: 7/19/2018: Standard Cognition venture capital transaction
Next: 7/19/2018: Reali venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs